CAR T therapies are expanding as multiple myeloma treatment options. In addition to the two currently FDA approved CAR T therapies (Abecma and Carvykti) which use a patient's own T cells in a production process, new allo (off-the-shelf) options are being developed in clinical trials. Dr. Jesus Berdeja is one of the leading CAR T experts in multiple myeloma and in this episode, he will share the current development taking place for allo CAR T therapies. Join us to learn more about this exciting field in myeloma research which may provide faster and more availalble treatment options for patients.  Note: Myeloma Crowd Radio is becoming HealthTree Podcast for Multiple Myeloma.